Changing the Healthcare Compliance Playing Field: The Responsible Corporate Officer Doctrine and Its Impact on Internal Investigations


July 10, 2010

Please Join our Panel of Healthcare Investigations Experts for a Complimentary CLE Breakfast Briefing on this Critical Issue. Participants will learn how increased use of the strict liability misdemeanor provision of the Food, Drug, and Cosmetic Act (FDCA) will change federal government-initiated investigations and internal investigations involving potential FDA violations. The FDA has called for more frequent prosecutions of individual corporate officers and directors. Strict liability means that your key people can be prosecuted even when they did not participate in, or know of, any underlying misconduct. Individuals convicted face imprisonment, substantial criminal fines and debarment.

Panelists include:

Jennifer Razor – Senior Counsel, Abbott Laboratories
David Resnicoff - Associate General Counsel and Vice-President, Ethics & Compliance, Baxter International
Preston Pugh – Partner, Pugh, Jones, Johnson & Quandt
Margaret “Peggy” Daley – Managing Director, Duff & Phelps

Everything begins with the right people.

See what else we are up to.